newsfilter
← Latest News
Business Wire·

Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

Royalties increased by 7% to $111.7 million in the second quarter of 2022, compared to the same quarter in 2021 Completed acquisition of the remaining approximately 40% of Entasis Therapeutics at a price of $2.20 per share for a consideration of $